IRIDEX to Host MicroPulse® Worldwide 3-Day Forum at the American Academy of Ophthalmology

MOUNTAIN VIEW, Calif., Oct. 17, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) announced today its Speakers' Forum program at the annual meeting of the American Academy of Ophthalmology to be held on October 18 – 21 at McCormick Place in Chicago. The Forum consists of a comprehensive 3-day schedule of activities at the IRIDEX booth featuring 13 MicroPulse presentations by 14 leading physicians, 8 of which are new to the IRIDEX podium.

The forum offers physicians from around the world an opportunity to share with their colleagues varying aspects of IRIDEX' propriety MicroPulse technology, such as clinical studies, protocols, practice integration, and financial implications. This educational program is intended to facilitate physician discussion in a relaxed peer-to-peer environment, and to offer opportunities to meet and engage with colleagues currently practicing, just getting started with, or interested in learning more about MicroPulse laser therapy.

Will Moore, IRIDEX President and CEO, commented, "Physicians are challenged with a rising number of patients suffering from glaucoma and retinal diseases, and we are pleased to create this opportunity for physicians to discuss the benefits and role of MicroPulse laser therapy to safely manage these diseases with sustainable, clinically effective results."

Select presentations from this year's program include the following:

• Why I Made the Jump to Fovea-Friendly MicroPulse Laser Therapy for the Macula, presented by Dr. Jeanne Rosenthal, Surgeon Director and Senior Attending Surgeon at the New York Eye and Ear Infirmary of Mount Sinai; and Dr. Julia Shulman, Director of Clinical Research and Associate Residency Program Director at Jamaica Hospital Medical Center in Queens and Clinical Instructor of Ophthalmology in the Pediatric Retina Division at New York Eye and Ear Infirmary of Mount Sinai. Sunday, October 19 at 11:30 AM
• Rethinking Our Regimen for Retinal Disease Management, presented by Ahad Mahootchi, MD, Medical Director of The Eye Clinic of Florida. Saturday, October 18 at 1:00 PM
• Laser Treatment Alternatives in Glaucoma, presented by Iqbal (Ike) Ahmed, MD, FRCSC, Assistant Professor and Research Fellowship Director, Department of Ophthalmology, University of Toronto. Sunday, October 19 at 2:30 PM

For the complete Speakers' Forum program, go to http://www.iridex.com/speakersforum. IRIDEX will be located at Booth #2621.

About MicroPulse
MicroPulse laser therapy is a tissue-sparing solution for the treatment of retinal diseases and glaucoma. With MicroPulse, a continuous-wave laser beam is chopped into a train of tiny, repetitive, low energy pulses separated by a brief rest period which allows the tissue to cool between laser pulses. MicroPulse laser therapy also can be used in conjunction with drug therapy, allowing complete and optimized management of retinal diseases and glaucoma without laser-induced damage.

About IRIDEX
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.

Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the effectiveness and safety of Company products, the Company's future financial performance, the Company's strategic plans and objectives, and trends in treatment and product usage. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

Logo - http://photos.prnewswire.com/prnh/20141001/149809

SOURCE IRIDEX Corporation

Related Links

http://www.iridex.com